EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration

Naoto Arimura, Chie Maeda, Kazunobu Aoyama iD, Namiko Yamaguchi, Ayumu Sugiura, Yasuko Takahashi, Ryouta Maeda, Tatsuya Ando, Makoto Kamata, Hideki Matsui iD, Maiko Tanaka

PLOS ONE · 21.11.2024 · 19 (11) · e0312090

DOI: 10.1371/journal.pone.0312090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 21.11.2024. Verfasst von Naoto Arimura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Kanagawa, Japan. Hauptthemen laut MEDLINE: Kainic Acid, Neurons, Monoacylglycerol Lipases, Neuroinflammatory Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation, a hallmark of neurodegenerative diseases, is associated with neuronal cell loss and cognitive dysfunction. Monoacylglycerol lipase (MAGL) is involved in neuroinflammation in the brain via the degradation of endocannabinoid 2-arachidonoylglycerol to arachidonic acid, a precursor of some eicosanoids; therefore, MAGL inhibitors are expected to have anti-inflammatory effects. We recently developed a reversible, selective, central nervous system penetrant, and orally available MAGL inhibitor, compound 4f . Compound 4f (1 mg/kg) robustly increased 2-arachidonoylglycerol levels and decreased arachidonic acid levels in the mouse brain. To examine whether compound 4f can suppress neuroinflammation and neuronal cell loss, kainic acid (KA)-injected mice were used as a neuroinflammation model in this study. Compound 4f (1 mg/kg) significantly decreased the cytokine and chemokine expression levels and suppressed neuronal cell loss in the hippocampi of mice. Compound 4f also ameliorated cognitive impairment in KA-injected mice. The cannabinoid receptor 1 antagonist, AM251, and cannabinoid receptor 2 antagonist, AM630, partly blocked the neuroprotective effects of compound 4f in the hippocampi of KA-injected mice. Gene expression profiles and pathway analyses revealed that compound 4f reversed the KA-induced changes in the expression of genes related to inflammation and neurotransmission. These results indicate that the selective and reversible MAGL inhibitor, compound 4f , can be used as a potential therapeutic agent for the treatment of neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kainic AcidNeuronsMonoacylglycerol LipasesNeuroinflammatory DiseasesCognitive DysfunctionAnimalsMiceMaleArachidonic AcidsGlyceridesEndocannabinoidsPiperidinesHippocampusBrainMice, Inbred C57BLEnzyme InhibitorsNeurodegenerative DiseasesNeuroprotective AgentsCytokines

Substanzen

Kainic AcidMonoacylglycerol LipasesArachidonic AcidsGlyceridesEndocannabinoidsglyceryl 2-arachidonatePiperidinesEnzyme InhibitorsNeuroprotective AgentsCytokines

Autor:innen und Institutionen

  • Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
  • DMPK, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
  • Computational Biology, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

ORCID-Profile: Kazunobu Aoyama, Hideki Matsui

Förderung

  • Takeda Pharmaceutical Company Limited

Zitieren

APA

Arimura, N., Maeda, C., Aoyama, K., Yamaguchi, N., Sugiura, A., Takahashi, Y., Maeda, R., Ando, T., Kamata, M., Matsui, H., & Tanaka, M. (2024). Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration. PLOS ONE, 19(11), e0312090. https://doi.org/10.1371/journal.pone.0312090

Vancouver

Arimura N, Maeda C, Aoyama K, Yamaguchi N, Sugiura A, Takahashi Y, et al. Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration. PLOS ONE. 2024;19(11):e0312090. doi:10.1371/journal.pone.0312090

BibTeX
@article{Arimura2024,
  author = {Arimura, Naoto and Maeda, Chie and Aoyama, Kazunobu and Yamaguchi, Namiko and Sugiura, Ayumu and Takahashi, Yasuko and Maeda, Ryouta and Ando, Tatsuya and Kamata, Makoto and Matsui, Hideki and Tanaka, Maiko},
  title = {Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {11},
  pages = {e0312090},
  doi = {10.1371/journal.pone.0312090}
}
Kostenlos starten →